Image For Activity Cover
Transcatheter Aortic Valve Replacement in Asia: Present Status and Future Perspectives (JACC: Asia December 2021)

Over the last decade, based on evidence from multiple randomized clinical trials, transcatheter aortic valve replacement (TAVR) has become the established treatment for patients with symptomatic severe aortic stenosis (AS). Despite the overwhelming expansion of TAVR in Western countries, initial uptake and widespread adoption of this procedure has been relatively delayed in Asian countries, owing to the high cost of devices, limited local health and reimbursement policies, and lack of specific training/proctoring program, specialized heart team, or dedicated infrastructure. Furthermore, it has not yet been determined whether there are substantial inter-racial and ethnic differences in clinical characteristics, comorbidities, and anatomic features, as well as procedural and long-term outcomes, in patients receiving TAVR. In this review, we provide not only a comprehensive look at the current status and outcomes of TAVR in Asian populations, compared with those of Western populations, but also the future perspective of TAVR in Asia.


JACC: Asia Editor-in-Chief 

Jian’an Wang, MD, PhD, FACC

CME Editor 

Kenneth A. Ellenbogen, MD


Cheol Hyun Lee, MD, PhD

Taku Inohara, MD, PhH

Kentaro Hayashida, MD, PhD

Duk-Woo Park, MD, PhD

Important Dates

Date of Release: December 21, 2021
Term of Approval/Date of CME/MOC/ECME Expiration: December 20, 2022

Availability: On-Demand
Expires on Dec 20, 2022
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By